Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them
Tuberculosis still remains a global health emergency, claiming 1.5 million lives in 2013. The bacterium responsible for this disease, Mycobacterium tuberculosis (M.tb), has successfully survived within hostile host environments, adapting to immune defence mechanisms, for centuries. This has resulted...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-03-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971214017172 |
| _version_ | 1818677450011312128 |
|---|---|
| author | Dimitrios Evangelopoulos Joana Diniz da Fonseca Simon J. Waddell |
| author_facet | Dimitrios Evangelopoulos Joana Diniz da Fonseca Simon J. Waddell |
| author_sort | Dimitrios Evangelopoulos |
| collection | DOAJ |
| description | Tuberculosis still remains a global health emergency, claiming 1.5 million lives in 2013. The bacterium responsible for this disease, Mycobacterium tuberculosis (M.tb), has successfully survived within hostile host environments, adapting to immune defence mechanisms, for centuries. This has resulted in a disease that is challenging to treat, requiring lengthy chemotherapy with multi-drug regimens. One explanation for this difficulty in eliminating M.tb bacilli in vivo is the disparate action of antimicrobials on heterogeneous populations of M.tb, where mycobacterial physiological state may influence drug efficacy. In order to develop improved drug combinations that effectively target diverse mycobacterial phenotypes, it is important to understand how such subpopulations of M.tb are formed during human infection. We review here the in vitro and in vivo systems used to model M.tb subpopulations that may persist during drug therapy, and offer aspirations for future research in this field. |
| first_indexed | 2024-12-17T08:59:33Z |
| format | Article |
| id | doaj.art-3ac00eb0ecac444ba2c8a920ce8165c2 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 1878-3511 |
| language | English |
| last_indexed | 2024-12-17T08:59:33Z |
| publishDate | 2015-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-3ac00eb0ecac444ba2c8a920ce8165c22022-12-21T21:55:47ZengElsevierInternational Journal of Infectious Diseases1201-97121878-35112015-03-0132C768010.1016/j.ijid.2014.11.028Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model themDimitrios Evangelopoulos0Joana Diniz da Fonseca1Simon J. Waddell2Centre for Clinical Microbiology, University College London, London, NW3 2PF, UKCentre for Clinical Microbiology, University College London, London, NW3 2PF, UKBrighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PX, UKTuberculosis still remains a global health emergency, claiming 1.5 million lives in 2013. The bacterium responsible for this disease, Mycobacterium tuberculosis (M.tb), has successfully survived within hostile host environments, adapting to immune defence mechanisms, for centuries. This has resulted in a disease that is challenging to treat, requiring lengthy chemotherapy with multi-drug regimens. One explanation for this difficulty in eliminating M.tb bacilli in vivo is the disparate action of antimicrobials on heterogeneous populations of M.tb, where mycobacterial physiological state may influence drug efficacy. In order to develop improved drug combinations that effectively target diverse mycobacterial phenotypes, it is important to understand how such subpopulations of M.tb are formed during human infection. We review here the in vitro and in vivo systems used to model M.tb subpopulations that may persist during drug therapy, and offer aspirations for future research in this field.http://www.sciencedirect.com/science/article/pii/S1201971214017172Mycobacterium tuberculosispersistence modelssubpopulationsphenotypic drug tolerancedrug discovery |
| spellingShingle | Dimitrios Evangelopoulos Joana Diniz da Fonseca Simon J. Waddell Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them International Journal of Infectious Diseases Mycobacterium tuberculosis persistence models subpopulations phenotypic drug tolerance drug discovery |
| title | Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them |
| title_full | Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them |
| title_fullStr | Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them |
| title_full_unstemmed | Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them |
| title_short | Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them |
| title_sort | understanding anti tuberculosis drug efficacy rethinking bacterial populations and how we model them |
| topic | Mycobacterium tuberculosis persistence models subpopulations phenotypic drug tolerance drug discovery |
| url | http://www.sciencedirect.com/science/article/pii/S1201971214017172 |
| work_keys_str_mv | AT dimitriosevangelopoulos understandingantituberculosisdrugefficacyrethinkingbacterialpopulationsandhowwemodelthem AT joanadinizdafonseca understandingantituberculosisdrugefficacyrethinkingbacterialpopulationsandhowwemodelthem AT simonjwaddell understandingantituberculosisdrugefficacyrethinkingbacterialpopulationsandhowwemodelthem |